Known targets — ChEMBL curated mechanism
ABL1BRAFDDR2EPHA2FGFR1FGFR2FLT1FLT4FRKKDRKITMAPK11NTRK1PDGFRAPDGFRBRAF1RETTEK
The experimentally established mechanism targets of Regorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 1.00 |
| ▸ | BRAF known ✓ | P15056 | 7/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 3/20 | 1.00 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 1.00 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 1.00 |
| ▸ | MAPK11 known ✓ | Q15759 | 2/20 | 1.00 |
| ▸ | DDR2 known ✓ | Q16832 | 2/20 | 1.00 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.83 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.83 |
| ▸ | FRK known ✓ | P42685 | 1/20 | 0.83 |
| ▸ | RIPK2 | O43353 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regorafenib SCHEMBL29351376 | 1.00 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL432230 | 1.00 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29496390 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2554008 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29555444 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2555101 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2552684 | 0.97 | RAF1 (0.93) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL30433607 | 0.94 | RAF1 (0.89) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL5086313 | 0.93 | RAF1 (0.87) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL22627130 | 0.92 | RAF1 (0.85) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13684 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075677-A | GM-CSF loaded tumor cell vaccine and application thereof in preventing and treating liver cancer | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137638-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TYARDI OPERATING CO INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4744729-A2 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Deciphera Pharmaceuticals, LLC (US) | 2026-05-20 | — | — | EP | claimed |
| US-12630624-B2 | Anti-IL-27 antibodies and uses thereof | Surface Oncology, LLC (US) | 2026-05-19 | — | — | US | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122055153-A | EGFR inhibitors for treating EGFR exon 20 mutation positive lung cancer | 安塔列斯疗法股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2022023759-A2 | METHODS OF PREPARING SOLID PARTICULATE MATERIALS | MICROPORE TECHNOLOGIES LIMITED (GB) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026510-A1 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | SEAGEN INC. (US) | 2022-02-03 | — | — | WO | claimed |
| CN-109276721-B | Targeting mesoporous polydopamine multifunctional nano diagnosis and treatment agent and preparation method and application thereof | 中山大学 | 2022-02-01 | — | — | CN | claimed |
| CN-112999169-B | Regorafenib-coated nano porous hydroxyapatite sustained-release microsphere as well as preparation method and application thereof | 广东医科大学 | 2022-02-01 | — | — | CN | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20220024777-A1 | NOVEL AMORPHOUS ACTIVE PHARMACEUTICAL INGREDIENTS COMPRISING SUBSTANTIALLY AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE | DISRUPTIVE PHARMA AB (SE) | 2022-01-27 | — | — | US | claimed |
| US-20220023213-A1 | NANOCRYSTALLINE EYE DROP, PREPARATION METHOD AND USE THEREOF | CHENGDU RUIMU PHARMACEUTICALS CO., LTD. (CN) | 2022-01-27 | — | — | US | claimed |
| WO-2022020648-A1 | INHIBITORS OF THE ARTEMIN PATHWAY FOR TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2022020720-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TCR2 Therapeutics Inc. (US) | 2022-01-27 | — | — | WO | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |